These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 10628763

  • 1. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.
    Transplantation; 1999 Oct 15; 68(7):997-1003. PubMed ID: 10532541
    [Abstract] [Full Text] [Related]

  • 3. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 4. Pediatric renal transplantation under tacrolimus-based immunosuppression.
    Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lombardozzi-Lane S, Gilboa N, Gritsch HA, Irish W, McCauley J, Fung JJ, Hakala TR, Simmons RL, Starzl TE.
    Transplantation; 1999 Jan 27; 67(2):299-303. PubMed ID: 10075598
    [Abstract] [Full Text] [Related]

  • 5. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 6. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.
    Transplantation; 1998 Oct 27; 66(8):1047-52. PubMed ID: 9808490
    [Abstract] [Full Text] [Related]

  • 7. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 8. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.
    Praghakaran K, Wise B, Chen A, Schwarz K, Colombani P.
    J Pediatr Surg; 1999 Jan 27; 34(1):112-5; discussion 115-6. PubMed ID: 10022154
    [Abstract] [Full Text] [Related]

  • 9. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T, Zwick DL, Rothberg PG, Warady BA.
    Pediatr Nephrol; 1999 Nov 27; 13(9):748-54. PubMed ID: 10603113
    [Abstract] [Full Text] [Related]

  • 10. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Studies of Pediatric Liver Transplantation Research Group.
    Liver Transpl; 2013 Jul 27; 19(7):730-40. PubMed ID: 23696264
    [Abstract] [Full Text] [Related]

  • 11. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF.
    J Pediatr; 1997 Jul 27; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [Abstract] [Full Text] [Related]

  • 12. [Remission of severe disease induced by CMV and lymphoproliferative post-transplant disease after changing the immunosuppressive regime].
    Gómez E, Melón S, Fresno MF, Tricas L, Navascués R, de Oña M, Herreros M, Alvarez Grande J.
    Nefrologia; 2002 Jul 27; 22(6):574-81. PubMed ID: 12516292
    [Abstract] [Full Text] [Related]

  • 13. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 14. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.
    J Pediatr Gastroenterol Nutr; 2001 Oct 15; 33(4):445-9. PubMed ID: 11698761
    [Abstract] [Full Text] [Related]

  • 15. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 15; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 16. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI.
    Transplantation; 1997 Sep 27; 64(6):848-52. PubMed ID: 9326409
    [Abstract] [Full Text] [Related]

  • 17. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.
    J Pediatr Gastroenterol Nutr; 2004 Feb 27; 38(2):198-203. PubMed ID: 14734884
    [Abstract] [Full Text] [Related]

  • 18. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun 27; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 19. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.
    McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W, CCTPT Study Group.
    Am J Transplant; 2008 May 27; 8(5):984-9. PubMed ID: 18416737
    [Abstract] [Full Text] [Related]

  • 20. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Nephrol Dial Transplant; 2012 Jul 27; 27(7):2971-9. PubMed ID: 22273720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.